Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

Eli Lilly’s Weight Loss Pill Doesn’t Work as Well as Investors Hoped. The Obesity Trade Is Wavering Again. Eli Lilly’s weight ...

Eli Lilly & Co.’s experimental pill helped patients shed roughly 11% of their body weight, about 25 pounds, in a late-stage ...

Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

In an 18-month clinical trial of the experimental GLP-1 pill orforglipron, about 60 percent of people lost at least 10 ...

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in ...

Eli Lilly's pill, orforglipron, is one step closer to becoming the first new, needle-free alternative in the booming market for weight loss and diabetes drugs.

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...

In eagerly awaited results from a new study, the pharmaceutical company Eli Lilly reports that a pill its scientists ...

Eli Lilly has hoped its candidate weight loss pill would safeguard its lead in the obesity market, but new results may prove ...

The experimental obesity medicine is one of two that could offer alternatives to weight-loss injections within the next year ...